Immunomedics Earlier Announced $250M Royalty Funding And Stock Purchase Agreement With Royalty Pharma; Co. Has Sold Rights To Sacituzumab Govitecan To Royalty Pharma For $175M And Also Received $75M Equity Investment, Valuing Shares At $17.15/Share

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!